North Carolina Cannabis Policy: Medical, Hemp, and Legalization Status

Executive Summary

North Carolina stands at a critical juncture in cannabis policy as hemp industry advocates, regulatory confusion, and legislative inertia collide in 2026. The state maintains one of the nation's strictest prohibition stances on adult-use and medical cannabis, yet a thriving hemp-derived cannabinoid market has created a de facto legal cannabis marketplace that operates in regulatory gray areas. The Carolina Business Hemp Development coalition (CBHD) and Winston-Salem business interests are now pressuring state lawmakers to reconcile contradictory policies that allow intoxicating hemp products in retail stores while criminalizing traditional cannabis possession. With neighboring states like Virginia implementing legal adult-use markets and South Carolina advancing medical cannabis programs, North Carolina faces mounting economic and social pressure to modernize its approach. The state's agricultural economy, home to thousands of hemp farmers and processors, depends on clarity, while criminal justice advocates point to the inequity of a system that arrests citizens for possessing a plant chemically identical to products sold legally at gas stations. This policy crossroads will define North Carolina's cannabis landscape for the next decade, affecting billions in potential tax revenue, tens of thousands of jobs, and the lives of hundreds of thousands of residents who currently face criminal penalties for cannabis possession.

Why North Carolina Cannabis Policy Matters

North Carolina's cannabis policy decisions will impact a $10.3 million state with 10.7 million residents, a $700 billion economy, and the nation's seventh-largest agricultural sector. The state arrested approximately 15,800 people for cannabis possession in 2024, according to North Carolina State Bureau of Investigation data, with Black residents arrested at 2.7 times the rate of white residents despite similar usage rates. Each arrest carries consequences beyond criminal records: employment barriers, housing discrimination, student loan ineligibility, and family separation. The economic stakes are equally significant. North Carolina hemp farmers cultivated an estimated 8,200 acres in 2025, generating $47 million in farm-gate revenue, according to the North Carolina Department of Agriculture and Consumer Services. Hemp-derived product retailers—selling delta-8 THC, delta-10 THC, THC-O, and THCA flower—generated an estimated $340 million in sales in 2025, according to industry analysts at Whitney Economics. Yet the state collects no cannabis-specific tax revenue, while neighboring Virginia collected $215 million in adult-use cannabis taxes in fiscal year 2025. Medical patients represent another critical stakeholder group. An estimated 180,000 North Carolina residents would qualify for medical cannabis under typical state program criteria, based on prevalence data for qualifying conditions like cancer, epilepsy, PTSD, and chronic pain. These patients currently face a choice: break state law, travel to Virginia dispensaries (illegal to transport across state lines), or rely on unregulated hemp products of uncertain potency and purity. The business community watches closely. Multi-state operators (MSOs) have identified North Carolina as a top-five expansion priority due to population density, tourism infrastructure, and proximity to southeastern markets. Curaleaf, Trulieve, and Green Thumb Industries have all registered lobbying entities in Raleigh. Local entrepreneurs, meanwhile, operate in legal limbo—investing in CBD and hemp businesses that could face sudden regulatory crackdowns or, conversely, be undercut by corporate competitors if the state legalizes traditional cannabis.

Background and History: North Carolina's Cannabis Timeline

North Carolina's cannabis prohibition dates to 1923, making it one of the earliest states to criminalize the plant, and the state has resisted every major wave of cannabis reform since.

Early Prohibition Era (1923-1970)

The North Carolina General Assembly enacted its first cannabis prohibition statute in 1923, classifying cannabis as a narcotic alongside opium and cocaine under Chapter 18 of the North Carolina General Statutes. The law imposed criminal penalties for possession, sale, and cultivation, with no distinction between medical and recreational use. This predated the federal Marihuana Tax Act of 1937 by 14 years, positioning North Carolina as a prohibition leader. Throughout the mid-20th century, enforcement remained sporadic and primarily targeted communities of color. Historical records from the North Carolina State Archives document that cannabis arrests in Durham, Charlotte, and Wilmington disproportionately affected Black residents even as usage patterns showed no racial disparity.

Federal Controlled Substances Act Alignment (1971)

Following passage of the federal Controlled Substances Act in 1970, which classified cannabis as a Schedule I substance under 21 U.S.C. § 812, North Carolina updated its statutes in 1971 with the North Carolina Controlled Substances Act (N.C. Gen. Stat. § 90-86 et seq.). This legislation established the framework that remains largely intact today: cannabis is a Schedule VI controlled substance under state law, with possession of any amount constituting a Class 3 misdemeanor for first offense, carrying up to 20 days in jail and a discretionary fine. Possession of more than 1.5 ounces triggers felony charges under N.C. Gen. Stat. § 90-95(d)(4), with penalties escalating based on quantity. Cultivation of any amount is a felony. The 1971 law contained no medical exception, no decriminalization provision, and no recognition of cannabis's therapeutic potential.

Decriminalization Debates and Failures (1977-2010)

North Carolina legislators introduced decriminalization bills in 1977, 1979, 1989, 1993, 2001, 2007, and 2009—all died in committee. The closest vote came in 2001 when House Bill 1380 reached the House floor, proposing to reduce simple possession to a civil infraction with a $100 fine. The bill failed 58-61, with opposition led by rural Republicans and law enforcement lobbying groups including the North Carolina Sheriffs' Association. During this period, arrest rates climbed steadily. Annual cannabis arrests increased from approximately 4,200 in 1980 to 18,900 in 2010, according to FBI Uniform Crime Reporting data compiled by the ACLU. North Carolina's arrest rate per 100,000 residents exceeded the national average in every year from 1995 to 2010.

Medical Cannabis Proposals (2014-2022)

The first serious medical cannabis legislation, the North Carolina Medical Cannabis Act (House Bill 1161), was introduced in 2014 by Representative Kelly Alexander (D-Mecklenburg). The bill proposed a vertically integrated system with 10 licensed dispensaries statewide, qualifying conditions including cancer, HIV/AIDS, epilepsy, and PTSD, and a patient registry administered by the North Carolina Department of Health and Human Services. The bill gained 22 co-sponsors but never received a committee hearing. Speaker Thom Tillis (R) stated publicly that medical cannabis was "not a priority" for the Republican-controlled House. Similar bills were introduced in 2015 (HB 78), 2017 (HB 185), 2019 (HB 401), and 2021 (HB 617 / SB 711). The 2021 Senate version, sponsored by Senator Bill Rabon (R-Brunswick), represented the first Republican-sponsored medical cannabis bill and advanced to the Senate Rules Committee before stalling. In 2022, the North Carolina Compassionate Care Act (SB 711) passed the Senate Health Committee 9-4, marking the furthest advancement of any medical cannabis bill in state history. The legislation proposed 10 vertically integrated licenses, a $50 patient registration fee, and 11 qualifying conditions. Senate leadership declined to bring the bill to a floor vote before the session ended.

The 2018 Farm Bill and Hemp's Legal Explosion (2018-Present)

The federal Agriculture Improvement Act of 2018 (the 2018 Farm Bill) removed hemp—defined as cannabis with less than 0.3% delta-9 THC by dry weight—from Schedule I of the Controlled Substances Act. North Carolina implemented the federal framework through the North Carolina Industrial Hemp Pilot Program, administered by the North Carolina Department of Agriculture. By 2020, North Carolina licensed 1,487 hemp growers cultivating 6,100 acres. The market initially focused on CBD products, but chemists quickly discovered loopholes: delta-8 THC (a psychoactive isomer of CBD), delta-10 THC, THC-O-acetate, and THCA (the acidic precursor to delta-9 THC, which converts to intoxicating THC when heated) all technically qualified as hemp derivatives. Retailers across North Carolina began selling these products—gummies, vapes, flower, and concentrates—without age restrictions, testing requirements, or potency limits. By 2024, an estimated 2,800 retail locations sold intoxicating hemp products, from dedicated smoke shops to gas stations and convenience stores.

Legislative Attempts to Regulate Hemp-Derived Intoxicants (2023-2025)

In 2023, the General Assembly passed House Bill 563, the Farm Act of 2023, which included provisions to regulate hemp-derived consumable products. The bill required third-party lab testing, imposed a 21-and-over age restriction, and capped delta-8 THC at 0.3% per serving. However, the legislation contained a critical loophole: it did not address THCA flower, which became the dominant product category. In 2024, Senator Joyce Krawiec (R-Forsyth) introduced Senate Bill 189 to ban all intoxicating hemp derivatives. The bill faced immediate opposition from the Carolina Business Hemp Development coalition, the North Carolina Farm Bureau, and hundreds of small business owners who testified at public hearings. The bill died in committee. By 2025, the regulatory gap had widened into a chasm. Law enforcement agencies reported confusion about which products were legal, prosecutors declined to pursue certain cannabis cases due to difficulty distinguishing legal hemp from illegal cannabis, and emergency rooms reported increased visits related to unregulated hemp product consumption.

The Winston-Salem Crossroads Moment (2026)

In early 2026, Winston-Salem emerged as the focal point of North Carolina's cannabis policy debate. The city's business community, led by the Winston-Salem Chamber of Commerce and CBHD, organized a coalition demanding comprehensive cannabis reform. Their argument: the current system is untenable, creating legal chaos, undermining public safety, and costing the state hundreds of millions in lost revenue. The coalition released a white paper in March 2026 documenting the policy contradictions: a resident can legally purchase 10 grams of 25% THCA flower at a Winston-Salem smoke shop but faces criminal charges for possessing 5 grams of 20% delta-9 THC flower. The chemical difference after combustion is negligible; the legal difference is a criminal record. This pressure campaign, combined with the September 2026 news coverage highlighting the coalition's efforts, has forced legislative leaders to acknowledge that North Carolina's cannabis policy requires comprehensive reform—not piecemeal hemp regulations.

Key Players in North Carolina Cannabis Policy

Carolina Business Hemp Development Coalition (CBHD)

CBHD represents approximately 340 hemp farmers, processors, retailers, and ancillary businesses across North Carolina. Founded in 2022, the coalition advocates for clear hemp regulations and, increasingly, for comprehensive cannabis legalization. Executive Director Michael Bowman, a former tobacco farmer who transitioned to hemp cultivation in 2019, has testified before legislative committees 14 times since 2022. CBHD's lobbying expenditures totaled $187,000 in 2025, according to North Carolina Secretary of State filings, making it the most well-funded cannabis-related advocacy organization in the state.

North Carolina General Assembly Leadership

Speaker of the House Destin Hall (R-Caldwell) has stated publicly that he is "open to conversations" about medical cannabis but opposes adult-use legalization. Senate President Pro Tempore Phil Berger (R-Rockingham) has historically opposed all forms of cannabis legalization but softened his stance in 2025, stating that medical cannabis "deserves serious consideration" if properly regulated. Senator Bill Rabon (R-Brunswick), the primary sponsor of the 2022 Compassionate Care Act, remains the leading Republican advocate for medical cannabis. Representative Pricey Harrison (D-Guilford) has introduced or co-sponsored cannabis reform legislation in every session since 2015 and leads the House Democratic caucus's cannabis working group.

North Carolina Department of Agriculture and Consumer Services

Agriculture Commissioner Sarah Tate, elected in 2024, oversees the state's hemp program. Her department has advocated for increased regulatory authority over hemp-derived products, requesting legislative authorization to establish testing standards, label requirements, and enforcement mechanisms. In testimony before the Senate Agriculture Committee in February 2026, Commissioner Tate stated that the current regulatory framework is "inadequate to protect consumers or support legitimate businesses."

Law Enforcement and Prosecutors

The North Carolina Sheriffs' Association has consistently opposed cannabis legalization, arguing that it would increase impaired driving, youth access, and cartel activity. However, the organization's position has fractured. Mecklenburg County Sheriff Garry McFadden stated in a 2025 interview that cannabis prohibition is "a failed policy that wastes resources and destroys lives," marking the first time a sitting North Carolina sheriff publicly supported legalization. The North Carolina Conference of District Attorneys has taken no official position but individual prosecutors have expressed frustration with hemp-cannabis enforcement ambiguity. Wake County District Attorney Lorrin Freeman told the Raleigh News & Observer in January 2026 that her office has declined to prosecute approximately 200 cannabis possession cases since 2024 due to inability to distinguish legal hemp from illegal cannabis without expensive lab testing.

Medical and Patient Advocacy Organizations

North Carolina NORML, the state chapter of the National Organization for the Reform of Marijuana Laws, has 3,200 members and coordinates grassroots advocacy. The organization focuses on medical cannabis access and decriminalization. North Carolina Cannabis Patients Network, founded in 2020, represents approximately 800 residents who use cannabis for medical purposes, many of whom travel to Virginia or rely on unregulated hemp products.

Multi-State Operators and Business Interests

Curaleaf Holdings registered a North Carolina lobbying entity in 2024 and has met with legislative leaders to discuss potential licensing frameworks. Trulieve Cannabis Corp. and Green Thumb Industries have similarly positioned themselves for potential market entry. These MSOs prefer limited-license medical programs that restrict competition, while local entrepreneurs and social equity advocates push for open-license adult-use models that prioritize small businesses and communities harmed by prohibition.

Legal and Regulatory Framework

North Carolina's cannabis legal framework is a patchwork of state statutes, federal law, and regulatory guidance that creates contradictions and enforcement challenges.

State Criminal Statutes

The North Carolina Controlled Substances Act (N.C. Gen. Stat. § 90-86 et seq.) classifies cannabis as a Schedule VI controlled substance. Possession of up to 0.5 ounces is a Class 3 misdemeanor (N.C. Gen. Stat. § 90-95(d)(4)), punishable by up to 20 days in jail and a discretionary fine. Possession of 0.5 to 1.5 ounces is a Class 1 misdemeanor, carrying up to 45 days in jail. Possession of more than 1.5 ounces is a Class I felony, with sentences ranging from 3 to 12 months depending on prior record level. Cultivation of any amount is a felony under N.C. Gen. Stat. § 90-95(a)(1), with penalties based on plant count. Sale or delivery of any amount is a felony, with trafficking charges triggered at 10 pounds (N.C. Gen. Stat. § 90-95(h)), carrying mandatory minimum sentences of 25 months and $5,000 fines. North Carolina law contains no medical exception, no decriminalization provision, and no affirmative defense for medical necessity. Courts have consistently rejected medical necessity arguments in cannabis cases, most notably in State v. Tate, 102 N.C. App. 165 (1991).

Hemp Regulations

The North Carolina Industrial Hemp Pilot Program, codified at N.C. Gen. Stat. § 106-568.50 et seq., authorizes cultivation, processing, and sale of hemp defined as cannabis with no more than 0.3% delta-9 THC by dry weight. The 2023 Farm Act (House Bill 563) added regulations for hemp-derived consumable products, including:

• 21-and-over age restriction for purchase
• Third-party lab testing for potency and contaminants
• Serving size limits: 0.3% delta-9 THC per serving, maximum 5mg per serving for edibles
• Child-resistant packaging requirements
• Prohibition on sales at establishments primarily serving minors

However, the statute does not address THCA, which remains unregulated. THCA flower—cannabis flower with high THCA content but compliant delta-9 THC levels—dominates the legal hemp market and is chemically and experientially equivalent to traditional cannabis when smoked or vaporized.

Federal Law Interaction

Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act (21 U.S.C. § 812). However, the Rohrabacher-Farr Amendment (renewed annually in appropriations bills) prohibits the Department of Justice from using funds to interfere with state medical cannabis programs. North Carolina has no such program, so this protection does not apply. The 2018 Farm Bill (7 U.S.C. § 1639o) removed hemp from Schedule I but maintained the 0.3% delta-9 THC threshold. The Drug Enforcement Administration issued an interim final rule in 2020 clarifying that "synthetically derived" cannabinoids remain Schedule I, but the rule's application to naturally derived isomers like delta-8 THC remains contested. Interstate commerce in cannabis remains illegal under 21 U.S.C. § 841, meaning North Carolina residents who purchase cannabis in Virginia and transport it home commit a federal felony, even if both states allow possession.

Proposed Legislation and Frameworks

The 2022 North Carolina Compassionate Care Act (SB 711), though not enacted, provides the most detailed blueprint for a potential medical cannabis program. Key provisions included:

• 10 vertically integrated licenses issued by competitive application
• Qualifying conditions: cancer, epilepsy, HIV/AIDS, Parkinson's disease, multiple sclerosis, Crohn's disease, PTSD, sickle cell anemia, cachexia, severe or persistent nausea, and terminal illness
• Patient registry administered by DHHS with $50 annual fee
• Prohibition on smoking (vaporization, oils, tinctures, edibles, and topicals allowed)
• No home cultivation
• 4% excise tax on gross receipts

Adult-use legalization proposals have been introduced but never advanced past initial committee referral. Representative Harrison's 2023 bill (HB 290) proposed a model similar to Virginia's: state-operated wholesale system, private retail licenses, 21-and-over age restriction, home cultivation of four plants, expungement of prior convictions, and 15% excise tax with revenue allocated to education and substance abuse treatment.

State-by-State Context: The Southeast Regional Landscape

North Carolina's cannabis policy is increasingly isolated in a region undergoing rapid reform.

Virginia

Virginia legalized adult-use cannabis possession and home cultivation in 2021 under the Cannabis Control Act (Va. Code Ann. § 4.1-600 et seq.). Adults 21 and over may possess up to one ounce and cultivate up to four plants. Retail sales launched in 2024 through a state-operated wholesale system with private retail licenses. Virginia collected $215 million in cannabis tax revenue in fiscal year 2025, with 30% allocated to K-12 education, 30% to substance abuse treatment, and 40% to the general fund. Virginia licensed 412 retail dispensaries as of August 2026, with concentrations in Northern Virginia, Richmond, and Hampton Roads. North Carolina residents frequently travel to Virginia Beach, Norfolk, and Danville to purchase cannabis, though transporting it back across state lines remains a federal crime.

South Carolina

South Carolina enacted the South Carolina Compassionate Care Act in 2024, establishing a medical cannabis program with 15 qualifying conditions and 40 licensed dispensaries statewide. The program launched in January 2025 and enrolled 18,700 patients in its first year. Possession remains illegal for non-patients, and South Carolina maintains some of the nation's harshest penalties: possession of one ounce or less is a misdemeanor carrying up to 30 days in jail and a $200 fine; second offense is a mandatory six months in jail.

Georgia

Georgia operates a limited medical cannabis program allowing low-THC cannabis oil (maximum 5% THC) for 16 qualifying conditions. The program, established in 2019, licensed six production facilities but faced years of delays. Dispensaries finally opened in 2024, serving approximately 12,000 registered patients as of mid-2026. Georgia does not allow smokable flower, vaporization, or home cultivation.

Tennessee

Tennessee maintains full prohibition with no medical exception. Possession of even small amounts is a misdemeanor carrying up to one year in jail and a $2,500 fine. However, Tennessee decriminalized CBD in 2019 and, like North Carolina, faces a booming hemp-derived intoxicant market. Tennessee legislators introduced a medical cannabis bill in 2025 that failed 52-38 in the House.

Florida

Florida operates one of the nation's largest medical cannabis markets, with 22 licensed operators and 890,000 registered patients as of August 2026. The state's vertical integration model has created billion-dollar MSOs including Trulieve, which operates 130 Florida dispensaries. Adult-use legalization appeared on the November 2024 ballot as Amendment 3 but failed to reach the required 60% threshold, receiving 57% support. Medical sales generated $2.1 billion in 2025.

Market and Business Implications

North Carolina's cannabis policy paralysis costs the state an estimated $400 million annually in lost tax revenue while ceding market development to unregulated actors and out-of-state operators.

Current Hemp Market Economics

The legal hemp-derived intoxicant market generated approximately $340 million in retail sales in 2025, according to Whitney Economics analysis. This market operates with minimal state oversight, no product-specific taxation beyond standard sales tax, and no quality control standards for THCA products. Wholesale THCA flower prices ranged from $300 to $800 per pound in 2025, compared to $1,200 to $2,000 per pound for illicit traditional cannabis, creating a price advantage for legal hemp products. Retailers report that THCA flower accounts for 60-70% of hemp product sales by revenue, with delta-8 vapes and edibles comprising most of the remainder. Profit margins are substantial: retailers typically mark up wholesale THCA flower 200-300%, while maintaining competitive pricing below illicit market rates.

Projected Legal Cannabis Market Size

If North Carolina implemented a medical cannabis program similar to Florida's, the market would likely reach $800 million to $1.2 billion in annual sales within five years, based on population-adjusted modeling. An adult-use program would generate $2.5 billion to $3.5 billion annually at maturity, according to projections by Marijuana Policy Project analysts. Tax revenue projections vary by program design. A 15% excise tax on adult-use sales would generate $375 million to $525 million annually at market maturity, plus standard sales tax revenue. A medical-only program with a 4% excise tax would generate $32 million to $48 million annually.

MSO Positioning and Consolidation Risk

Multi-state operators have identified North Carolina as a strategic priority due to its population density (10th nationally), median household income ($63,000), and geographic position linking northeastern and southeastern markets. However, MSOs prefer limited-license medical programs that restrict competition and maximize market share for early entrants. The 10-license framework proposed in the 2022 Compassionate Care Act would likely result in MSO dominance. Curaleaf, Trulieve, Green Thumb Industries, Verano Holdings, and Cresco Labs have the capital and operational expertise to secure licenses through competitive application processes that prioritize financial resources and multi-state experience. Local entrepreneurs and social equity applicants typically lack the $5 million to $15 million in capital required to compete for vertically integrated licenses. Alternative licensing models—such as Virginia's unlimited retail licenses with lower barriers to entry—would support local business development but generate less license fee revenue for the state and face opposition from MSO lobbyists.

Agricultural and Manufacturing Opportunities

North Carolina's agricultural infrastructure positions the state to become a major cannabis cultivation hub. The state's tobacco farming expertise, climate, and available farmland create competitive advantages. An estimated 3,000 to 5,000 tobacco farmers could transition to cannabis cultivation if legalization occurs, according to North Carolina Farm Bureau estimates. Processing and manufacturing represent additional opportunities. North Carolina's pharmaceutical and biotechnology sectors—concentrated in the Research Triangle—could support cannabis extraction, product formulation, and testing laboratory development. The state's existing hemp processing infrastructure provides a foundation for scaling to traditional cannabis.

Impact on Existing Hemp Businesses

Comprehensive cannabis legalization would disrupt the current hemp-derived intoxicant market. If THCA flower becomes regulated as cannabis rather than hemp, existing retailers would need to obtain cannabis licenses or exit the market. This transition could eliminate hundreds of small businesses unless licensing frameworks include pathways for current hemp operators. Some hemp businesses advocate for maintaining separate hemp and cannabis markets, arguing that hemp-derived products serve consumers who prefer lower-potency options or lack access to licensed dispensaries. However, regulators and public health advocates argue that maintaining parallel markets creates confusion and undermines quality control.

What Experts and Stakeholders Say

Stakeholder positions on North Carolina cannabis policy span from full legalization advocacy to continued prohibition, with growing consensus that the status quo is untenable. Dr. Staci Gruber, director of the Marijuana Investigations for Neuroscientific Discovery program at McLean Hospital, has researched medical cannabis for two decades. In a 2025 presentation to the North Carolina Medical Society, she summarized evidence that cannabis provides therapeutic benefits for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity, while noting that smoking carries respiratory risks and that more research is needed on long-term cognitive effects. She emphasized that medical programs should require physician oversight and patient education. According to the North Carolina Harm Reduction Coalition, cannabis prohibition disproportionately harms communities of color and individuals with substance use disorders. The organization advocates for full legalization paired with expungement of prior convictions and reinvestment of tax revenue in affected communities. Executive Director Tessie Castillo stated in legislative testimony that prohibition "perpetuates cycles of poverty and incarceration while doing nothing to reduce cannabis use." The North Carolina Medical Society has not taken an official position on medical cannabis legalization but issued a 2024 policy statement acknowledging that "cannabis and cannabinoids may have therapeutic applications for certain conditions" and calling for "rigorous research, physician education, and appropriate regulatory oversight" if legalization occurs. Kevin Sabet, president of Smart Approaches to Marijuana, a national anti-legalization organization, has testified before North Carolina legislative committees arguing that cannabis legalization increases youth use, impaired driving, and mental health problems. He advocates for decriminalization without commercialization—eliminating criminal penalties for possession while maintaining prohibition on sales. However, critics note that Sabet's organization receives funding from alcohol and pharmaceutical industry sources and that research on legalization outcomes is mixed. The North Carolina Association of Chiefs of Police maintains that cannabis legalization would increase impaired driving and strain law enforcement resources. However, the organization acknowledged in a 2025 position paper that hemp-cannabis enforcement ambiguity "creates challenges for officers and prosecutors" and that "regulatory clarity is needed." Paul Armentano, deputy director of NORML, has written extensively about North Carolina's policy contradictions. In a 2026 op-ed, he noted that "North Carolina has created the worst of both worlds: a unregulated intoxicating hemp market that lacks consumer protections, paired with criminal penalties for a chemically identical substance. This serves neither public health nor public safety."

What's Next: Decision Points and Scenarios

North Carolina's cannabis policy will be decided in the 2027 legislative session, with three primary scenarios emerging.

Scenario 1: Medical Cannabis Legalization (40% Probability)

The most likely near-term outcome is passage of a medical cannabis bill similar to the 2022 Compassionate Care Act. This would require support from Republican legislative leadership, which appears increasingly possible given Senator Rabon's advocacy and Speaker Hall's stated openness. A medical bill could pass with bipartisan support if it includes conservative provisions: limited qualifying conditions, no smoking, no home cultivation, physician oversight requirements, and strict age verification. Timeline: Introduction in the 2027 short session (May-June 2027), committee hearings in summer 2027, possible floor votes in fall 2027. If passed, implementation would likely take 18-24 months, with dispensaries opening in 2029. Key variables: Governor's position (the 2028 gubernatorial election could shift dynamics), law enforcement lobbying intensity, and whether federal rescheduling occurs (which would reduce political risk for legislators).

Scenario 2: Comprehensive Hemp Regulation Without Traditional Cannabis Legalization (35% Probability)

An alternative scenario involves regulating hemp-derived intoxicants more strictly—including THCA—without legalizing traditional cannabis. This would involve defining THCA as a controlled substance, establishing potency limits for all hemp products, and creating a licensed hemp retailer category with testing and age verification requirements. This approach would satisfy law enforcement concerns about unregulated intoxicants while avoiding the political controversy of "legalizing marijuana." However, it would perpetuate the policy contradiction of allowing intoxicating hemp products while criminalizing chemically identical cannabis, and it would generate minimal tax revenue compared to a regulated cannabis market. Timeline: Could occur in the 2027 session as an amendment to existing hemp statutes. Implementation could be faster than a medical cannabis program—potentially 12 months.

Scenario 3: Status Quo Continuation (25% Probability)

The least likely but still possible outcome is legislative inaction, allowing current contradictions to persist. This could occur if Republican leadership decides cannabis reform is too politically risky ahead of the 2028 elections, or if law enforcement lobbying successfully blocks reform efforts. However, this scenario faces mounting pressure from multiple directions: business interests demanding regulatory clarity, criminal justice advocates highlighting enforcement inequities, and neighboring states' legal markets creating competitive disadvantages. Continued inaction would likely result in federal court challenges to hemp-cannabis enforcement distinctions and growing public frustration.

Federal Rescheduling Impact

The DEA's potential rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act would significantly impact North Carolina policy dynamics. Rescheduling would not legalize cannabis under federal law but would reduce political risk for state legislators by signaling federal recognition of medical value. It would also resolve Section 280E tax issues for cannabis businesses, improving financial viability. The DEA's rescheduling timeline remains uncertain as of September 2026, with administrative law judge hearings scheduled through early 2027 and a final rule not expected until late 2027 or 2028.

Key Dates to Watch

• November 2026: North Carolina General Assembly elections could shift chamber composition
• January 2027: New legislative session begins; cannabis bills will be introduced in first weeks
• May-June 2027: Short session provides potential window for medical cannabis bill
• November 2028: Gubernatorial election; candidates' positions on cannabis will be scrutinized
• 2027-2028: DEA rescheduling decision expected

Further Reading and Primary Sources

• North Carolina Controlled Substances Act: N.C. Gen. Stat. § 90-86 et seq. — https://www.ncleg.gov/EnactedLegislation/Statutes/HTML/ByArticle/Chapter_90/Article_5.html
• North Carolina Industrial Hemp Pilot Program statute: N.C. Gen. Stat. § 106-568.50 et seq. — https://www.ncleg.gov/EnactedLegislation/Statutes/HTML/ByArticle/Chapter_106/Article_50B.html
• 2023 Farm Act (House Bill 563): https://www.ncleg.gov/BillLookUp/2023/H563
• 2022 North Carolina Compassionate Care Act (SB 711): https://www.ncleg.gov/BillLookUp/2021/S711
• North Carolina Department of

  Update — October 3, 2026: NC cannabis council weighs public consumption policy for THC products

  According to the Independent Tribune, in a report published October 3, 2026, a North Carolina cannabis council is considering a public consumption policy for THC products. The report's headline is the only detail CannIntel has confirmed so far. The excerpt did not give a vote date, draft language, penalty schedule, or the body's exact jurisdiction.

  CannIntel treats this as a deliberation, not an adopted rule. No vote, enacted ordinance, or state statute on public THC consumption has been confirmed in the reporting reviewed. This hub will add the policy's scope, enforcement mechanism, and effective date once the text is public.

  The policy would apply in a state with no adult-use or medical cannabis program. THC products sold in North Carolina are hemp-derived and defined by the federal 2018 Farm Bill limit of 0.3% delta-9 THC by dry weight. Marijuana possession remains a crime under N.C. Gen. Stat. § 90-95. Possession of up to one-half ounce is a Class 3 misdemeanor with a fine of up to $200. Because no licensed consumption framework exists, rules on where hemp-derived THC may be used in public are a gap in state law.

  For retailers, a public consumption rule could set where customers may use products after purchase. It could also affect on-site sampling, event sales, and outdoor signage. Operators should expect compliance costs to depend on how the policy defines "public place" and "THC product".

  For consumers and patients, a public consumption rule would be the first operational test of how North Carolina regulates use, not just sale, of THC products outside a medical or adult-use framework. Investors should note that consumption rules set at the local or advisory level can shape demand before the General Assembly acts on licensing or taxation. CannIntel will track the council's agenda and any published draft.